Exclusive Production of Imaging Contrast Media

Spain: Merck Opens Production Facility for Meglumine Exclusive Production of Imaging Contrast Media

17.01.2017Editor: Alexander Stark

Merck announced the opening of a new, ICH Q7-compliant facility dedicated to the production of meglumine, a unique pharmaceutical excipient and component of contrast imaging media.

Related Companies

Merck KGaA

Maag Pump Systems AG

TRM Filter d.o.o.

Frewitt fabrique de machines SA

Merck opens the only facility in Europe solely dedicated to meglumine production.
(Source: Merck)

Darmstadt/Germany — Merck announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility, the company claims. Therefore, the manufacture of meglumine had to meet the same stringent regulatory and quality requirements as APIs.

"Our new facility was optimized around the manufacturing process to achieve greater efficiencies and meets the most stringent quality standards for manufacturing meglumine," said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation, Life Science. "The result is a high level of confidence in quality and security of supply for our customers."

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:44464580)

Spain: Merck Opens Production Facility for Meglumine Exclusive Production of Imaging Contrast Media

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes